Tilray Pops 50% as Marijuana Clinical Trials Power Growth
*By Carlo Versano*
As cannabis companies like Canopy Growth and Aurora align themselves with consumer beverage brands, Tilray ー the pot stock that's up a cool 600 percent since its July IPO and has added more than $7 billion to its market cap just on Wednesday ー is taking a different tack.
The Canada-based company is making a "really strong push" into clinical trials for medical marijuana, said Bethany Gomez, director of research for consulting firm Brightfield Group.
That strategy, illustrated by Tuesday's announcement that Tilray got DEA clearance to import cannabis to the U.S. for a University of California San Diego research study, appears to be paying off.
Tilray shares were up by as much as 50 percent Wednesday ー adding to gains of nearly 30 percent the day before ー giving the company a market cap of more than $21 billion, above that of much older, established companies like Best Buy and CBS. The stock, which debuted at $17 a share two months ago, now trades over $200.
"They're aligning themselves very well in a lot of key areas," Gomez said.
Tilray is essentially making a bet that it can get into a "preferred stance" to negotiate with international governments that are beginning to grant small numbers of licenses for medical marijuana research, Gomez said.
By partnering with research facilities like the one at UCSD, Tilray has a "first mover advantage" when those licenses are given out, she said.
But whether optimism on that front justifies the stock's price gains is up for debate. On Wednesday morning Citron Research, known for making bearish bets on stocks, [tweeted](https://twitter.com/CitronResearch/status/1042395769372909568) that Tilray's jump was "beyond comprehension." The firm said, "We are short and will hold a manageable position until rationality sets in."
Tilray is just one of several marijuana stocks that are experiencing highs. On average, the group is up about 30 percent since August, [according to IHS Markit](https://www.nytimes.com/2018/09/17/business/dealbook/shorting-cannabis-stocks-costly.html).
But it's a long game, Gomez said. "There's going to be ups, and there's going to be downs."
For full interview [click here](https://cheddar.com/videos/tilray-shares-hit-new-high).
An independent watchdog within the IRS reports that while taxpayer services have vastly improved, the agency is still too slow to resolve identity theft cases. And National Taxpayer Advocate Erin Collins says those delays are “unconscionable.” Erin M. Collins said in the report released Wednesday that overall the 2024 filing season went smoothly, though IRS delays in resolving identity theft victim assistance cases are worsening. It took nearly 19 months to resolve self-reported identity theft cases as of January, and Wednesday's report states that now it takes 22 months to resolve these cases.
Amazon.com Inc. surpassed $2 trillion in market value for the first time in afternoon trading on Wednesday. The push higher for Amazon’s stock market valuation comes a little more than a week after Nvidia hit $3 trillion and briefly became the most valuable company on Wall Street. Nvidia’s chips are used to power many AI application and its valuation has soared as a result. Amazon has also been making big investments in AI as global interest has grown in the technology. Most of the company’s focus has been on business-focused products.
Climate change doesn’t just mean more extreme weather – it also leads to billions of dollars in lost productivity, tourism, and stresses infrastructure.
It’s an annual tradition: the Fed’s banking ‘stress test.’ A year after the regional banking crisis, there are good reasons to make sure they’re prepped.
Summer is upon us, which means weddings, trips overseas, and trips to see Taylor Swift. Avoid a “Cruel Summer” with these budget-friendly tips and tricks.
While Nvidia's meteoric rise led it to briefly dethrone Microsoft as the world's biggest public company, there's a lot more going on in this market than A.I.
